NEPHRX CORPORATION
NephRx Corporation, a biotechnology company, engages in the discovery and development of therapeutic products for the treatment of acute kidney failure, renal disorders, and diseases of the gastrointestinal tract. It provides NX001, which is useful for the treatment of delayed graft function in kidney transplant patients; and NX002, a peptide that is derived from the naturally occurring growth factor AMP-18. The company was incorporated in 1995 and is based in Kalamazoo, Michigan.
NEPHRX CORPORATION
Industry:
Biotechnology Health Care Therapeutics
Founded:
1995-01-01
Address:
Kalamazoo, Michigan, United States
Country:
United States
Website Url:
http://www.nephrx.com
Total Employee:
1+
Status:
Active
Contact:
269-372-8703
Total Funding:
6.22 M USD
Technology used in webpage:
SPF Nginx DOSarrest Uniregistry
Current Employees Featured
Founder
Official Site Inspections
http://www.nephrx.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "NephRx Corporation"
NephRx Corporation - Crunchbase Company Profile
NephRx Corporation, a biotechnology company, engages in the discovery and development of therapeutic products for the treatment of acute kidney failure, renal disorders, and diseases of the gastrointestinal tract.See details»
NephRx Corporation - Products, Competitors, Financials, …
NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of kidney failure/disease and diseases of the …See details»
NephRx Corporation - Contacts, Employees, Board Members
NephRx Corporation develops therapeutic products for acute kidney failure, renal disorders, and diseases of the gastrointestinal tract.See details»
NephRx Corporation - Funding, Financials, Valuation & Investors
NephRx Corporation develops therapeutic products for acute kidney failure, renal disorders, and diseases of the gastrointestinal tract.See details»
NephRx Corp. Starts Human Trial Of Kidney Transplant Assist Drug
Nov 11, 2010 · NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of kidney failure, is in development for the prevention …See details»
NephRx | Scientist.com
NephRx focuses on the discovery and development of therapeutic peptides for acute kidney disease and gastrointestinal disorders.See details»
NephRx Corporation - VentureRadar
NephRx Corporation VentureRadar profile. Find out more about NephRx Corporation including the VentureRadar Innovation and Growth scores, Similar Companies and more.See details»
NephRx Corp. Receives Orphan Drug Designation for NX001 for …
KALAMAZOO, Mich., Aug. 18 /PRNewswire/ -- NephRx Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead …See details»
NephRx Kidney Drug Gets 'Orphan' Designation - CBS Detroit
Aug 18, 2010 · Kalamazoo-based NephRx Corp. announced that the United States Food and Drug Administration has granted orphan drug designation to its product NX001 for the …See details»
Nephrx Asset Profile - Preqin
NephRx is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure/disease and diseases of the gastrointestinal …See details»
NephRx Corp. Awarded U.S. Patent for NX002 for Treatment of
KALAMAZOO, Mich., Nov. 30, 2011 (GLOBE NEWSWIRE) -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in …See details»
NephRx Corporation - Tech Stack, Apps, Patents & Trademarks
Nov 17, 2024 · NephRx Corporation develops therapeutic products for acute kidney failure, renal disorders, and diseases of the gastrointestinal tract.See details»
NephRx Corporation - CB Insights
Feb 8, 2010 · See NephRx Corporation funding rounds, investors, investments, exits and more. Evaluate their financials based on NephRx Corporation's post-money valuation and revenue.See details»
NX-002 - Drug Targets, Indications, Patents - Synapse
NX-002: a Unspecified growth factor receptor modulators Drug, Initially developed by NephRx Corp., Now, its global highest R&D status is Pending, Mechanism: Unspecified growth factor …See details»
NephRx Corp. Initiates Phase I Trial of its Lead Drug Being …
Nov 11, 2010 · NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the …See details»
NephRx Corp. Reports NX002 is Effective in Preclinical Model of …
Oct 7, 2010 · NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal …See details»
NephRx Corporation - Crunchbase
NephRx Corporation develops therapeutic products for acute kidney failure, renal disorders, and diseases of the gastrointestinal tract.See details»
NephRx Corporation Initiates Phase I Trial of its Lead Drug Being ...
Nov 11, 2010 · NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the …See details»
NephRx Corporation Reports NX002 is Effective in Preclinical
KALAMAZOO, Mich., Oct. 7 /PRNewswire/ -- NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when tested in …See details»
NepRx Gets Patent For Peptide Aimed At Gastrointestinal Tract
Nov 30, 2011 · KALAMAZOO – NephRx Corporation Wednesday announced the issuance of U.S. patent for its novel peptide NX002, which currently is in preclinical development for the …See details»